Navigation Links
OrbusNeich Introduces the Combo™ Dual Therapy Stent at TCT 2011
Date:11/10/2011

SAN FRANCISCO, Nov. 10, 2011 /PRNewswire/ -- OrbusNeich today announced the introduction of the Combo Dual Therapy Stent during a breakfast symposium chaired by Martin B. Leon, M.D., professor of medicine and director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, New York, at Transcatheter Cardiovascular Therapeutics (TCT) 2011 in San Francisco.

Dr. Leon introduced the Combo Stent as the first in a new category of dual therapy stents (DTS). Combo leverages a partitioned effect that combines an abluminal sirolimus drug elution for the control of neointimal proliferation with OrbusNeich's Genous pro-healing technology for the acceleration of endothelial coverage.

"The Combo Dual Therapy Stent is OrbusNeich's latest innovation to leverage Genous, our proprietary pro-healing stent technology, to address the significant clinical risk of delayed or absent healing that faces drug eluting stents today," said Al Novak, OrbusNeich's chairman of the board, president and CEO. "Today's symposium included exceptional presentations delivered by thought leaders in the field, and it served as the ideal venue to introduce the novel concept of a dual therapy stent to the world."

Interim results from EGO-COMBO, an optical coherence tomography (OCT) study of early healing with the Combo Stent, were presented this morning by Prof. Stephen W.L. Lee, M.D., chief of cardiology, professor and senior consultant, Department of Medicine, Queen Mary Hospital, University of Hong Kong, showing that Combo achieved 70 percent strut coverage in less than 50 days.

The prospective, single center study included 60 patients treated with a total of 87 Combo Dual Therapy Stents. Frequency domain (FD) OCT was performed serially at baseline post-stenting, at early follow-up to determine early neointimal healing and at nine months to determine OCT late loss. The percentage of healed struts was used as a proxy for endothelial coverage, t
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire-iReach/ -- Today leading ... all new data ranking Pharmaceutical web sites for usability, ... Sciences, User Experience Cloud platform, which compares how people ... on the web. The top three performers ... convert people overall. The bottom performers have usability problems, ...
(Date:6/19/2013)... 19, 2013 /PRNewswire-iReach/ -- In its first ... pharmaceutical company dedicated to advancing development of ... sustained release drug therapies in patient disease ... announced the acquisition of Enzon Pharmaceutical,s PEGylation ... associated product pipeline. Acquisition of this technology ...
(Date:6/19/2013)... 19, 2013  Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... number one overall pharmacy equipment vendor in the ... a leading independent healthcare research firm, compared the ... its annual rankings. Omnicell also received the prestigious ...
Breaking Medicine Technology:Sunovion tops new Change Sciences User Experience Rankings for Pharmaceutical Industry while McNeil-PPC ranks worst overall 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4
...   Unigene Laboratories, Inc. (OTCBB: UGNE), ... of peptide-based therapeutics, announced that Ashleigh Palmer, President and ... the Biotech Showcase™ 2012 in San Francisco, CA on ... p.m. ET).  Mr. Palmer,s presentation will include an overview of ...
... Md., Jan. 4, 2012 /PRNewswire-iReach/ -- ... pharmaceutical company focused exclusively in the HIV-1 therapeutic ... to provide medicinal chemistry services to support DFH ... maturation inhibitor drugs. Maturation inhibitors are a novel ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
(Date:6/19/2013)... 2013 McGuff Pharmaceuticals, Inc. ... Drug Application (ANDA) for Hydroxyprogesterone Caproate Injection, USP 250mg/mL, ... Squibb’s drug fomerly known as Delalutin™. We are ... the anticipated approval and market introduction dates for McGuff’s ... status of our pending ANDA, to date, McGuff has ...
(Date:6/19/2013)... Calculating insurance rates is a complex process that ... and of course their own company policies. This process ... from company to company, and why by shopping around for ... often save, as car insurance can be a hefty expense ... the top factors that determine their car insurance premiums. ...
(Date:6/19/2013)... June 19, 2013 Sudden cardiac arrest can ... sets in an average of 5 minutes after cardiac arrest, ... 11 minutes. This means that death is highly probable if ... readily available for use. In response to this dire reality, ... to Save Lives Act (H.R. 2308) which would provide support ...
(Date:6/19/2013)... June 19, 2013 Anant Goel, CEO at ... changing rapidly. The first industrial revolution began in Britain in ... industry… when the factory was born. The second industrial revolution ... the moving assembly line and ushered in the age of ... the 21st century. Manufacturing is going digital and this could ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Indosoft ... Center ACD for Asterisk, announced today the ... 5.7. This enhancement offers improved options for extracting, ... dashboards for effective contact center management. , Large ... real-time captured as it happens from the call ...
Breaking Medicine News(10 mins):Health News:Current Progress Towards ANDA Approval of Hydroxyprogesterone Caproate Injection, USP 2Health News:icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums 2Health News:icandrive.ca Provides Tips to Understand the Top Factors That Affect Car Insurance Premiums 3Health News:AED.com Supports Automated External Defibrillator (AED) Legislation in Schools in US and UK 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 2Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 3Health News:RKNet Studios Announced Cognitions Bridge Intelligence Games for Fun, Cognitive Skills Testing and Development for Success in Life 4Health News:Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity 2
... 2011) Active children need to be watered with ... than a sports drink or water itself, say researchers ... summer weather, says Brian Timmons, research director of the ... principal investigator of the study. "Children become ...
... care costs arising from pressure ulcers, commonly known as ... in emergency departments, according to new research from the ... are at high risk for pressure ulcers in part ... researchers found that while the average cost of upgrading ...
... 17, 2011) Patients with clinically diagnosed superficial vein thrombosis (SVT), ... that commonly resolves on its own without treatment, are four ... a dangerous, often life-threatening condition, according to study results ... Journal of the American Society of Hematology (ASH). ...
... Reporter , WEDNESDAY, Aug. 17 (HealthDay News) -- Researchers ... useful in identifying women who have a higher risk ... This particular antibody, which was detected in blood, ... called mesothelin. This protein is present in advanced ovarian ...
... The Medical College of Wisconsin investigating latex allergy in ... health strategy to prevent allergic sensitization is by stopping ... studies pointed out this association of latex allergy to ... completely confirm this link in specific workers. Reducing the ...
... treating chronic wounds on patients in the United States. These ... than six million people who have them. The most common ... to venous disease (conditions related to or caused by veins ... but the quality of evidence showing which treatments work better ...
Cached Medicine News:Health News:Better mattresses improve care, cut hospital costs: U of T study 2Health News:Common vein condition increases risk for developing life-threating blood clots 2Health News:Blood Antibody May Signal Start of Ovarian Cancer 2Health News:Blood Antibody May Signal Start of Ovarian Cancer 3Health News:Using powder-free latex gloves reduces latex allergy rate in health care workers 2Health News:Johns Hopkins Evidence-based Practice Center awarded $475,000 project 2Health News:Johns Hopkins Evidence-based Practice Center awarded $475,000 project 3
Fenestrated 14 mm blades. Wide extension of blade for protection of lids. Self-locking mechanism. Dull finish....
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Infant model. Blades: 7 mm. Solid blades with locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
Medicine Products: